Cargando…

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

IMPORTANCE: Approximately one-quarter of the global population have latent tuberculosis infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths annually. Methotrexate, cyclosporine, and tumor necrosis factor inhibitors may be associated with increased risk of TB and L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elewski, Boni E., Baddley, John W., Deodhar, Atul A., Magrey, Marina, Rich, Phoebe A., Soriano, Enrique R., Soung, Jennifer, Bao, Weibin, Keininger, Dorothy, Marfo, Kwaku, Patekar, Manmath, Sharma, Abhishek, Shete, Abhijit, Lebwohl, Mark Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527940/ https://www.ncbi.nlm.nih.gov/pubmed/33001147 http://dx.doi.org/10.1001/jamadermatol.2020.3257

Ejemplares similares

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
por: GOTTLIEB, Alice B., et al.
Publicado: (2022)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021)

Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019)

Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies
por: Deodhar, Atul A., et al.
Publicado: (2020)

A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
por: van der Horst-Bruinsma, Irene, et al.
Publicado: (2021)

Correction to: Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019)

Role of secukinumab in ankylosing spondylitis with tubercular uveitis
por: Mahendradas, Padmamalini, et al.
Publicado: (2020)

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients
por: Moskal, Mateusz, et al.
Publicado: (2022)

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
por: Emery, Paul, et al.
Publicado: (2018)

Effectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC)
por: Ajibade, Adeola, et al.
Publicado: (2023)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
por: Deodhar, A., et al.
Publicado: (2019)

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
por: Schreiber, Stefan, et al.
Publicado: (2019)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
por: Colombo, Giorgio L, et al.
Publicado: (2018)

Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
por: Kiltz, Uta, et al.
Publicado: (2022)

A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab
por: Magrey, Marina, et al.
Publicado: (2019)

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
por: Purmonen, Timo, et al.
Publicado: (2019)

Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
por: Tahir, Hasan, et al.
Publicado: (2020)

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
por: Deodhar, Atul A., et al.
Publicado: (2016)

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
por: Ehrlich, Dean, et al.
Publicado: (2018)

Relapsing Polychondritis following Treatment with Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature
por: Zheutlin, Alexander, et al.
Publicado: (2018)

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
por: Maksymowych, Walter P., et al.
Publicado: (2018)

OA21 Ankylosing Spondylitis management with Secukinumab but related Inflammatory bowel disease phenomenon
por: Iqbal, Sultan, et al.
Publicado: (2022)

Successful Treatment of SAPHO Syndrome Complicated with Ankylosing Spondylitis by Secukinumab: A Case Report
por: Tu, Wei, et al.
Publicado: (2023)

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
por: Kiltz, Uta, et al.
Publicado: (2020)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database
por: Bittar, Mohamad, et al.
Publicado: (2022)

Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs
por: Zhou, Yu, et al.
Publicado: (2020)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2014)

Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
por: Tseng, Jui-Cheng, et al.
Publicado: (2020)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
por: Wahono, Cesarius Singgih, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8mtvhq850khimk5v7gperntdqb